How Genetic Testing Has Changed for Patients With Breast Cancer
Kevin Hughes, MD, discusses how genetic testing has changed and how much testing should be done for patients with breast cancer.
Watch
Sponsored: The Evolving Role of Stem Cell Transplant in Older AML Patients
Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br />
Differences Observed in Urinary Microbiota Among Patients With Bladder Cancer
Massimo Lazzari, MD, discusses findings from an analysis of the urinary microbiota in patients with bladder cancer.
Future Directions in Treating HER2+ Breast Cancer
Dose Escalation & Managing Toxicities of Neratinib
Understanding the ExteNET Trial
Testing for HER2 Expression in Breast Cancer Patients
Prognosis of a HER2+ Breast Cancer Patient
A Stage II HER2+ Breast Cancer Patient
A 54-Year-Old Woman With Stage 2 HER2+ Breast Cancer
Effects of Para-aortic Lymph Node Metastases on Endometrial Cancer Survival
Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Immunotherapy Induces Responses in Subtypes of Sarcomas
Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.
Treating Patients With Indolent Lymphomas in the Relapsed Setting
Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Progress Made in Treating BRAF V600E+ Metastatic NSCLC
Progression of BRAF V600E+ Metastatic NSCLC
Dabrafenib Plus Trametinib for the Treatment of mNSCLC
Impact of Next-Generation Sequencing for Treating mNSCLC
A 62-Year-Old Woman With BRAF V600E+ Metastatic NSCLC
A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
Data Demonstrate Efficacy of 3 PARP Inhibitors in Ovarian Cancer
Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.
Delivering Optimal Outcomes in Prostate Cancer Despite Adverse Events
Eugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.
Future Directions in EGFR+ NSCLC
EGFR+ mNSCLC: Monitoring Treatment Response and Next Steps
EGFR-VEGF Inhibition for First-Line EGFR+ mNSCLC Treatment
EGFR-TKIs in First-Line EGFR+ Metastatic NSCLC
Current Molecular Testing Strategies for EGFR+ NSCLC
Impressions of a Woman With EGFR+ Metastatic NSCLC
A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Therapy Approach in High-Risk Prostate Cancer
Understanding the CARD and PROfound Trials